NYNazif Alperen Yıldırım

Nazif Alperen Yıldırım

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nazif Alperen Yıldırım has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinicopathologic features of microcystic pigmented chromophobe renal cell carcinoma

    by Busra Yaprak Bayrak, Murat Oktay, Melek Buyukgok, Fadime Eda Gökalp Satıcı, Merve Meryem Kıran, Fatma Cevik Kaya, Ganime Coban, Meltem Oznur, Seda Koc Sahin, Onder Kara, et al.

  • BAP1 loss and TFE3 immunoexpression in high-grade clear cell renal cell carcinoma

    by Murat Oktay, Nazif Alperen Yildirim, Hatice Nese Dogan, Ganime Coban, Zeynep Nur Karaca, Selva Kabul, Havva Merve Dinc, Busra Yaprak Bayrak, Ece Ozturk, Liang Cheng, et al.

  • The State of Pathology Training and Practice in Türkiye: A Cross-Sectional Survey of Residents, Specialists, and Academic Staff

    by Nazif Alperen Yildirim, Ece Ozturk, Raif Omer Kasap, Duygu Turkbey, Busra Yaprak Bayrak, Mahmut Akgul

    Background: Working conditions and training quality among pathologists in Türkiye remain insufficiently characterized. This study assessed professional experiences, satisfaction, workload, burnout, academic engagement, and career outlook among pathology residents, specialists, and academic staff practicing in Türkiye. Methods: A cross-sectional, web-based survey was distributed to pathologists in Türkiye. The questionnaire covered demographics, institutional characteristics, motivations for choosing pathology, workload and overtime, satisfaction, burnout indicators, academic activity, and career expectations. Responses were analyzed descriptively and compared across career stages using the Kruskal–Wallis test for continuous or ordinal variables and the Chi-squared or Fisher exact test for categorical variables. Predictors of general job satisfaction were evaluated using multiple linear regression. Results: Overall, 232 pathologists responded; 229 reported career stage, including residents (43.2%), specialists (41.5%), and academic staff (15.3%). Most participants worked in training and research hospitals or public universities. The leading motivations for choosing pathology were limited patient contact, absence of night shifts, and interest in the field. Burnout within the previous 6 months was reported by 76.1% and constant fatigue by 84.7%. General job satisfaction was low across all groups, particularly regarding protected research time, workload, and work–life balance. In regression analysis, overtime and administrative work predicted lower satisfaction, whereas diagnostic and research activities predicted higher satisfaction. Overtime was largely uncompensated and commonly expected by supervisors. Conclusion: Pathology practice in Türkiye is marked by pervasive burnout, chronic fatigue, uncompensated overtime, and low satisfaction, with residents disproportionately affected. Reforms are needed to improve workload distribution, training conditions, work–life balance, and protected research time.

  • L1CAM expression in eosinophilic solid and cystic renal cell carcinoma: clinicopathologic and immunophenotypic insights from a multicenter cohort

    by Selva Kabul, Busra Yaprak Bayrak, Busra Ozbek, Elif Ozsagir, Nazif Alperen Yıldırım, Ece Ozturk, Hamed Jafarzadeh, Burcu Biltekin, Melek Buyukgok, Nuran Sungu, et al.

  • "Renal cell carcinoma, not otherwise specified” is not a sufficient diagnostic classification

    by Nazif Alperen Yildirim, Busra Yaprak Bayrak, Liang Cheng, Mahmut Akgul

  • The Evaluation of Renal Tumor Diagnostics in Global Pathology Practice

    by Nazif Alperen Yıldırım, Laila Farid, Dilara Akbulut, Sana Malik, Maryna Slisarenko, Dilek Ertoy Baydar, Manana Jikurashvili, Elza Tjio, Yazgi Koy, Onur Ertunc, et al.

    Background: The 2022 World Health Organization (WHO) fifth Edition introduced major revisions to renal neoplasm classification, incorporating novel and molecularly defined entities. However, the extent to which these advances are adopted in routine pathology practice remains unclear. This international survey evaluated the global diagnostic work-up of kidney tumors, including access to ancillary tests (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], next-generation sequencing [NGS]) and familiarity with the current classification. Methods: A 30-question online survey was distributed via SurveyMonkey to pathologists involved in renal tumor diagnostics between January and July 2024. The survey assessed demographics, practice setting, training background, WHO classification familiarity, and availability of IHC and molecular testing. Responses were analyzed using descriptive and inferential statistics. Results: Of 427 respondents, 399 (94.8%) reported encountering kidney tumors and were included, representing 45 countries. The most represented were the United States (18.8%), Egypt (15.8%), Turkey (12.6%), the United Kingdom (8.8%), and India (7.3%). Nearly half (49.4%) had >10 years of practice, 41.1% lacked formal genitourinary pathology training, and 70.7% worked in academic settings. IHC was widely available (96.0%), whereas access to FISH (50.1%) and NGS (43.8%) was limited. High-resource academic centers had significantly greater access to molecular diagnostics than community settings (all p < .001). Kidney-specific molecular panels were available in only 18.1% of institutions. Emerging biomarkers (SDHB, FH, cathepsin K, TFE3, TRIM63) were substantially less available than conventional markers. Although 66.3% reported familiarity with the WHO classification, 33.6% cited barriers such as rapid updates, financial constraints, and workload. Conclusions: Marked global disparities persist in renal tumor diagnostics. While IHC is widely accessible, advanced molecular tools and novel biomarkers remain unevenly distributed, underscoring the need for targeted educational and resource-sharing strategies.

  • Perivascular epithelioid cell tumours of the genitourinary tract: clinicopathological features and molecular landscape

    by Busra Yaprak Bayrak, Mahmut Akgul, Michael Cheng, Nazif Alperen Yıldırım, Ankur R. Sangoi, Liang Cheng

    Perivascular epithelioid cell tumours (PEComas) comprise a distinctive and biologically heterogeneous family of mesenchymal neoplasms defined by perivascular epithelioid differentiation and dual melanocytic and smooth muscle‐like immunophenotypes. Within the genitourinary (GU) tract, renal tumours are historically designated as angiomyolipoma (AML) and represent the most common and biologically informative manifestation of PEComa, serving as the conceptual reference model for understanding PEComa across different organ sites. Extrarenal GU PEComas, on the other hand, are rare, morphologically diverse and frequently pose significant diagnostic challenges, particularly in limited biopsy material. This review synthesizes contemporary clinicopathological, immunohistochemical and molecular data on GU PEComas, with emphasis on diagnostic pathology, risk stratification and practical diagnostic interpretation. This also emphasizes classification based on shared molecular drivers rather than organ site or legacy terminology and provides a guide for accurate diagnosis, risk assessment and interpretation of PEComas in daily pathology practice.

  • Open Access

    Marked attenuation of P63 expression in plasmacytoid urothelial carcinoma with expanded immunohistochemical framework including E‐cadherin, P120 , HER2 and TRPS1

    by Busra Yaprak Bayrak, Kemal Kosemehmetoglu, Busra Ozbek, Sercan Simsek, Murat Oktay, Ganime Coban, Dilara Irem Arslan Kahraman, Egemen Akıncıoglu, Melek Buyukgok, Selin Colak, et al.

    Aims: Plasmacytoid urothelial carcinoma (PUC) is an aggressive morphological subtype characterized by discohesive single‐cell infiltration and frequent loss of epithelial adhesion. Although p63 is widely regarded as a reliable urothelial lineage marker in conventional urothelial carcinoma, its expression may be reduced or absent in plasmacytoid tumours, creating an important diagnostic pitfall. This multi‐institutional study aimed to characterize the clinicopathological and immunohistochemical profile of PUC, with particular emphasis on p63 immunoreactivity and its relationship to adhesion‐related markers and other diagnostically relevant immunophenotypes. Methods and results: A total of 93 cases initially diagnosed as PUC were retrospectively reviewed across multiple centres. After histopathological re‐evaluation, 70 confirmed cases were included. Immunohistochemical analysis was performed for p63, e‐cadherin, p120 catenin, TRPS1, HER2/Neu . The cohort comprised 70 patients with a median age of 66.5 years (IQR, 59.8–72.0) and a strong male predominance of 85.7% (60/70). Most specimens were obtained from transurethral resections (64.3%, 45/70) and radical cystectomy specimens (34.3%, 24/70). The median tumour size was 3.0 cm (IQR, 1.0–5.0), and the median proportion of plasmacytoid differentiation was 80% (IQR, 20–100). Morphologically, tumours were classified as classic plasmacytoid in 65.7% (46/70), pleomorphic in 22.9% (16/70) and desmoplastic in 11.4% (8/70). Concurrent variant histology was identified in 21.4% (15/70), most commonly micropapillary (12.9%, 9/70) and sarcomatoid (7.1%, 5/70) components. Lymphovascular invasion was present in 51.4% (36/70), and concomitant carcinoma in situ was detected in 35.7% (25/70). Immunohistochemically, p63 expression was retained in only 10.0% of tumours (7/70). HER2 membranous overexpression was observed in 58.6% (41/70), while loss of E‐cadherin expression was highly prevalent (84.3%, 59/70). Aberrant p120 catenin expression was common, with cytoplasmic localization in 72.9% (51/70) and complete loss in 17.1% (12/70). TRPS1 immunostaining was available in 54 tumours and was negative in 92.6% of evaluable cases (50/54). Conclusion: PUC demonstrates a distinctive immunophenotype characterized by frequent loss of p63 and disruption of the e‐cadherin/p120 adhesion complex. Recognition of p63 attenuation, together with adhesion‐related markers and HER2 status, provides a useful diagnostic framework for distinguishing this aggressive subtype from conventional urothelial carcinoma and its mimickers.

  • Clinical, pathological, and radiological features of the cystic renal lesions

    by Nazif Alperen Yildirim, Yasemin Yuyucu Karabulut, Duygu Turkbey, Ece Ozturk, Dilara Irem Arslan Kahraman, Murat Oktay, Serkan Berdibek, Busra Yaprak Bayrak, Mesude Tosun, Ganime Çoban, et al.

  • Intratesticular Serous Borderline Tumor: A Clinicopathologic and Molecular Analysis of Four Tumors With Literature Review

    by Nazif Alperen Yildirim, Busra Yaprak Bayrak, Gupse Turan, Sumeyye Sahin, Hale Kivrak, Deniz Pinar Baran, Gunes Guner, Mahmut Akgul

    Ovarian-type epithelial tumors of the testis are uncommon, with serous borderline tumors (SBTs) representing the most. Intratesticular localization is exceptionally rare, with fewer than 20 tumors described in the literature. We report 4 intratesticular SBTs and provide a clinicopathologic and molecular characterization along with a literature review. The patients ranged from 16 to 83 years and presented with scrotal swelling, discomfort, or a palpable mass. Serum tumor markers were within normal limits in all patients. Imaging studies revealed well-circumscribed cystic lesions with internal papillary projections. Gross examination of the tumors showed unilocular cystic lesions containing serous to hemorrhagic fluid within the testis. Histopatholologically, the tumors showed complex intracystic papillary projections lined by ciliated pseudostratified columnar or cuboidal epithelium with minimal atypia and no stromal invasion. Psammoma bodies and focal heterotopic ossification were variably observed. Immunohistochemically, all tumors were diffusely positive for WT1, estrogen receptor, and progesterone receptor, with variable PAX8 and keratin 7 (KRT7) expression, and were negative for calretinin and D2.40, confirming Müllerian differentiation. Targeted next-generation sequencing revealed pathogenic alterations in AKT1 (p.E17K), CHEK2 (p.D438Y), and TERT promoter (c.-124C > T) in one patient, expanding the molecular spectrum of testicular SBTs; the remaining sequenced tumors were wild-type. All patients remained disease-free during follow-up. Intratesticular SBTs are rare Müllerian-type neoplasms that can closely mimic other more aggressive neoplasms. Recognition of their characteristic morphology and immunoprofile, together with emerging molecular insights, is helpful to avoid misdiagnosis and overtreatment.